OPS going forward...At the end of Q3 2022 sales were $ 26 399 M
Assuming sales in the Q4.............$ 10 601 M +/-
Total expected sales for 2022 Total $ 37 000 M
From an investor presentation :
the expected Sales for 2025 .............$ 100 000 M
for a growth of 270 %vin 3 years
If so, share price to ''zoom'' accordingly but first step is the FDA approval in a couple of months and European approval early in 2023.